Lilac Biosciences Inc, a life sciences company spun out of the Giuliani RNA Center at Brown University, and medical device company Soin Neuroscience announced on Thursday the publication of a joint clinical review in Frontiers in Pain Research.

The article, 'New Insight into RNA Biomarkers in Neuropathic Pain: A Clinician and Neuroscientist Roadmap to Translational Testing and Treatment Monitoring', presents a practical framework for translating RNA biomarker science into clinical tools that may help assess and monitor neuropathic pain.

According to Lilac, neuropathic pain has historically been difficult to quantify, leaving clinicians to rely largely on patient-reported symptoms when evaluating disease severity and treatment response. The company says that the review addresses this challenge from both clinical and laboratory perspectives, examining how RNA biomarkers -- including RNA modifications such as N6-methyladenosine, or m6A -- could help characterise pain, support treatment selection and monitor a patient's response over time.

Together, the authors outline a translational roadmap intended to move RNA biomarker research from molecular measurement toward practical clinical applications.

The publication builds on an ongoing collaboration between Lilac Biosciences and Soin Neuroscience, combining Lilac's quantitative RNA workflows and molecular-analysis capabilities with Soin Neuroscience's clinical pain-management and neuromodulation expertise.